We are experiencing 4 week turn-around time in review of submissions and resubmissions. We recommend commencing this process concurrently with your ethics submission and allowing at least 8 weeks for registration to be completed from date of first submission. We currently do not have the capacity to expedite reviews.

Note also there are delays to review of updates. We appreciate your patience.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/show/NCT03465540




Registration number
NCT03465540
Ethics application status
Date submitted
8/03/2018
Date registered
14/03/2018
Date last updated
18/03/2021

Titles & IDs
Public title
Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected Relapsed or Refractory Hematological Malignancies
Scientific title
A Phase 1 Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected Relapsed or Refractory Hematological Malignancies
Secondary ID [1] 0 0
20170173
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Multiple Myeloma 0 0
Acute Myeloid Leukemia 0 0
Non-Hodgkins Lymphoma 0 0
Myelodysplastic Syndrome 0 0
AML 0 0
MDS 0 0
NHL 0 0
Condition category
Condition code
Cancer 0 0 0 0
Leukaemia - Acute leukaemia
Cancer 0 0 0 0
Leukaemia - Chronic leukaemia
Cancer 0 0 0 0
Children's - Leukaemia & Lymphoma
Blood 0 0 0 0
Haematological diseases
Blood 0 0 0 0
Other blood disorders

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - AMG 397
Treatment: Drugs - Dexamethasone
Treatment: Drugs - Azacitidine

Experimental: Part 1A: AMG 397 Dose Escalation - This arm includes subjects with multiple myeloma (MM) or non-Hodgkin's lymphoma (NHL).

Experimental: Part 1B: AMG 397 Dose Escalation - This arm includes subjects with acute myeloid leukemia (AML).

Experimental: Part 2A: AMG 397 Monotherapy - This arm includes subjects with AML or myelodysplastic syndrome (MDS).

Experimental: Part 2B: AMG 397 Monotherapy - This arm includes subjects with AML in Japan only.

Experimental: Part 2C: AMG 397 Monotherapy - This arm includes subjects with MM.

Experimental: Part 3A: AMG 397 + Azacitidine Combotherapy - This arm includes subjects MDS.

Experimental: Part 3B: AMG 397+ Azacitidine Combotherapy - This arm includes subjects AML.

Experimental: Part 3C: AMG 397+ Dexamethasone Combotherapy - This arm includes subjects MM.


Treatment: Drugs: AMG 397
AMG 397 will be administered orally once or twice weekly as part of a 28-day treatment cycle.

Treatment: Drugs: Dexamethasone
Dexamethasone will be administered intravenously (IV) or orally on Days 1, 8, 15, and 22 of each 28-day cycle.

Treatment: Drugs: Azacitidine
Azacitidine will be administered intravenously (IV) or subcutaneously (SC) daily for the first 7 days of a 28-day cycle.

Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Part 1A: Subject Incidence of Dose-Limiting Toxicity
Timepoint [1] 0 0
28 days
Primary outcome [2] 0 0
Part 1A: Incidence of Treatment-Emergent Adverse Events
Timepoint [2] 0 0
Up to 19 months
Primary outcome [3] 0 0
Part 1A: Incidence of Treatment-Related Adverse Events
Timepoint [3] 0 0
Up to 19 months
Primary outcome [4] 0 0
Part 1A: Incidence of Clinically Significant Changes in Vital Signs
Timepoint [4] 0 0
Up to 8 months
Primary outcome [5] 0 0
Part 1A: Incidence of Clinically Significant Changes in Physical Examinations
Timepoint [5] 0 0
Up to 8 months
Primary outcome [6] 0 0
Part 1A: Incidence of Clinically Significant Changes in Electrocardiograms (ECGs)
Timepoint [6] 0 0
Up to 8 months
Primary outcome [7] 0 0
Part 1A: Incidence of Clinically Significant Changes in Clinical Laboratory Tests
Timepoint [7] 0 0
Up to 8 months
Primary outcome [8] 0 0
Part 1B: Subject Incidence of Dose-Limiting Toxicity
Timepoint [8] 0 0
28 days
Primary outcome [9] 0 0
Part 1B: Incidence of Treatment-Emergent Adverse Events
Timepoint [9] 0 0
Up to 19 months
Primary outcome [10] 0 0
Part 1B: Incidence of Treatment-Related Adverse Events
Timepoint [10] 0 0
Up to 19 months
Primary outcome [11] 0 0
Part 1B: Incidence of Clinically Significant Changes in Vital Signs
Timepoint [11] 0 0
Up to 8 months
Primary outcome [12] 0 0
Part 1B: Incidence of Clinically Significant Changes in Physical Examinations
Timepoint [12] 0 0
Up to 8 months
Primary outcome [13] 0 0
Part 1B: Incidence of Clinically Significant Changes in Electrocardiograms (ECGs)
Timepoint [13] 0 0
Up to 8 months
Primary outcome [14] 0 0
Part 1B: Incidence of Clinically Significant Changes in Clinical Laboratory Tests
Timepoint [14] 0 0
Up to 8 months
Primary outcome [15] 0 0
Part 2A: Subject Incidence of Dose-Limiting Toxicity
Timepoint [15] 0 0
28 days
Primary outcome [16] 0 0
Part 2A: Incidence of Treatment-Emergent Adverse Events
Timepoint [16] 0 0
Up to 19 months
Primary outcome [17] 0 0
Part 2A: Incidence of Treatment-Related Adverse Events
Timepoint [17] 0 0
Up to 19 months
Primary outcome [18] 0 0
Part 2A: Incidence of Clinically Significant Changes in Vital Signs
Timepoint [18] 0 0
Up to 8 months
Primary outcome [19] 0 0
Part 2A: Incidence of Clinically Significant Changes in Physical Examinations
Timepoint [19] 0 0
Up to 8 months
Primary outcome [20] 0 0
Part 2A: Incidence of Clinically Significant Changes in Electrocardiograms (ECGs)
Timepoint [20] 0 0
Up to 8 months
Primary outcome [21] 0 0
Part 2A: Incidence of Clinically Significant Changes in Clinical Laboratory Tests
Timepoint [21] 0 0
Up to 8 months
Primary outcome [22] 0 0
Part 2B: Subject Incidence of Dose-Limiting Toxicity
Timepoint [22] 0 0
28 days
Primary outcome [23] 0 0
Part 2B: Incidence of Treatment-Emergent Adverse Events
Timepoint [23] 0 0
Up to 19 months
Primary outcome [24] 0 0
Part 2B: Incidence of Treatment-Related Adverse Events
Timepoint [24] 0 0
Up to 19 months
Primary outcome [25] 0 0
Part 2B: Incidence of Clinically Significant Changes in Vital Signs
Timepoint [25] 0 0
Up to 8 months
Primary outcome [26] 0 0
Part 2B: Incidence of Clinically Significant Changes in Physical Examinations
Timepoint [26] 0 0
Up to 8 months
Primary outcome [27] 0 0
Part 2B: Incidence of Clinically Significant Changes in Electrocardiograms (ECGs)
Timepoint [27] 0 0
Up to 8 months
Primary outcome [28] 0 0
Part 2B: Incidence of Clinically Significant Changes in Clinical Laboratory Tests
Timepoint [28] 0 0
Up to 8 months
Primary outcome [29] 0 0
Part 2B: Maximum Observed Concentration (Cmax) of AMG 397
Timepoint [29] 0 0
Up to 6 months
Primary outcome [30] 0 0
Part 2B: Area Under the Concentration-time Curve (AUC) for AMG 397
Timepoint [30] 0 0
Up to 6 months
Primary outcome [31] 0 0
Part 2B: Clearance (CL) of AMG 397
Timepoint [31] 0 0
Up to 6 months
Primary outcome [32] 0 0
Part 2B: Half-life (t1/2) of AMG 397
Timepoint [32] 0 0
Up to 6 months
Primary outcome [33] 0 0
Part 2C: Subject Incidence of Dose-Limiting Toxicity
Timepoint [33] 0 0
28 days
Primary outcome [34] 0 0
Part 2C: Incidence of Treatment-Emergent Adverse Events
Timepoint [34] 0 0
Up to 19 months
Primary outcome [35] 0 0
Part 2C: Incidence of Treatment-Related Adverse Events
Timepoint [35] 0 0
Up to 19 months
Primary outcome [36] 0 0
Part 2C: Incidence of Clinically Significant Changes in Vital Signs
Timepoint [36] 0 0
Up to 8 months
Primary outcome [37] 0 0
Part 2C: Incidence of Clinically Significant Changes in Physical Examinations
Timepoint [37] 0 0
Up to 8 months
Primary outcome [38] 0 0
Part 2C: Incidence of Clinically Significant Changes in Electrocardiograms (ECGs)
Timepoint [38] 0 0
Up to 8 months
Primary outcome [39] 0 0
Part 2C: Incidence of Clinically Significant Changes in Clinical Laboratory Tests
Timepoint [39] 0 0
Up to 8 months
Primary outcome [40] 0 0
Part 3A: Subject Incidence of Dose-Limiting Toxicity
Timepoint [40] 0 0
28 days
Primary outcome [41] 0 0
Part 3A: Incidence of Treatment-Emergent Adverse Events
Timepoint [41] 0 0
Up to 19 months
Primary outcome [42] 0 0
Part 3A: Incidence of Treatment-Related Adverse Events
Timepoint [42] 0 0
Up to 19 months
Primary outcome [43] 0 0
Part 3A: Incidence of Clinically Significant Changes in Vital Signs
Timepoint [43] 0 0
Up to 8 months
Primary outcome [44] 0 0
Part 3A: Incidence of Clinically Significant Changes in Physical Examinations
Timepoint [44] 0 0
Up to 8 months
Primary outcome [45] 0 0
Part 3A: Incidence of Clinically Significant Changes in Electrocardiograms (ECGs)
Timepoint [45] 0 0
Up to 8 months
Primary outcome [46] 0 0
Part 3A: Incidence of Clinically Significant Changes in Clinical Laboratory Tests
Timepoint [46] 0 0
Up to 8 months
Primary outcome [47] 0 0
Part 3B: Subject Incidence of Dose-Limiting Toxicity
Timepoint [47] 0 0
28 days
Primary outcome [48] 0 0
Part 3B: Incidence of Treatment-Emergent Adverse Events
Timepoint [48] 0 0
Up to 19 months
Primary outcome [49] 0 0
Part 3B: Incidence of Treatment-Related Adverse Events
Timepoint [49] 0 0
Up to 19 months
Primary outcome [50] 0 0
Part 3B: Incidence of Clinically Significant Changes in Vital Signs
Timepoint [50] 0 0
Up to 8 months
Primary outcome [51] 0 0
Part 3B: Incidence of Clinically Significant Changes in Physical Examinations
Timepoint [51] 0 0
Up to 8 months
Primary outcome [52] 0 0
Part 3B: Incidence of Clinically Significant Changes in Electrocardiograms (ECGs)
Timepoint [52] 0 0
Up to 8 months
Primary outcome [53] 0 0
Part 3B: Incidence of Clinically Significant Changes in Clinical Laboratory Tests
Timepoint [53] 0 0
Up to 8 months
Primary outcome [54] 0 0
Part 3C: Subject Incidence of Dose-Limiting Toxicity
Timepoint [54] 0 0
28 days
Primary outcome [55] 0 0
Part 3C: Incidence of Treatment-Emergent Adverse Events
Timepoint [55] 0 0
Up to 19 months
Primary outcome [56] 0 0
Part 3C: Incidence of Treatment-Related Adverse Events
Timepoint [56] 0 0
Up to 19 months
Primary outcome [57] 0 0
Part 3C: Incidence of Clinically Significant Changes in Vital Signs
Timepoint [57] 0 0
Up to 8 months
Primary outcome [58] 0 0
Part 3C: Incidence of Clinically Significant Changes in Physical Examinations
Timepoint [58] 0 0
Up to 8 months
Primary outcome [59] 0 0
Part 3C: Incidence of Clinically Significant Changes in Electrocardiograms (ECGs)
Timepoint [59] 0 0
Up to 8 months
Primary outcome [60] 0 0
Part 3C: Incidence of Clinically Significant Changes in Clinical Laboratory Tests
Timepoint [60] 0 0
Up to 8 months
Secondary outcome [1] 0 0
Part 1A: Objective Response Rate (ORR) for Multiple Myeloma (MM) Subjects - Response criteria per International Myeloma Working Group - Uniform Response Criteria (IMWG-URC).
Timepoint [1] 0 0
Up to 19 months
Secondary outcome [2] 0 0
Part 1A: Objective Response Rate (ORR) for Non-Hodgkin's Lymphoma (HNL) Subjects - Response criteria per Lugano Classification.
Timepoint [2] 0 0
Up to 19 months
Secondary outcome [3] 0 0
Part 1A: Progression-free survival (PFS)
Timepoint [3] 0 0
Up to 19 months
Secondary outcome [4] 0 0
Part 1A: Overall Survival (OS)
Timepoint [4] 0 0
Up to 19 months
Secondary outcome [5] 0 0
Part 1A: Time to Response
Timepoint [5] 0 0
Up to 19 months
Secondary outcome [6] 0 0
Part 1A: Duration of Response (DoR)
Timepoint [6] 0 0
Up to 19 months
Secondary outcome [7] 0 0
Part 1A: Maximum Observed Concentration (Cmax) of AMG 397
Timepoint [7] 0 0
Up to 6 months
Secondary outcome [8] 0 0
Part 1A: Time of Maximum Observed Concentration (Tmax) of AMG 397
Timepoint [8] 0 0
Up to 6 months
Secondary outcome [9] 0 0
Part 1A: Area Under the Concentration Time Curve (AUC) of AMG 397
Timepoint [9] 0 0
Up to 6 months
Secondary outcome [10] 0 0
Part 1A: Clearance (CL) of AMG 397
Timepoint [10] 0 0
Up to 6 months
Secondary outcome [11] 0 0
Part 1A: Half-life (t1/2) of AMG 397
Timepoint [11] 0 0
Up to 6 months
Secondary outcome [12] 0 0
Part 1B: Objective Response Rate (ORR) for Acute Myeloid Leukemia (AML) Subjects - Response criteria per Revised International Working Group (IWG).
Timepoint [12] 0 0
Up to 19 months
Secondary outcome [13] 0 0
Part 1B: Objective Response Rate (ORR) for Myelodysplastic Syndrome (MDS) Subjects - Response criteria per Revised International Working Group (IWG).
Timepoint [13] 0 0
Up to 19 months
Secondary outcome [14] 0 0
Part 1B: Progression-free survival (PFS)
Timepoint [14] 0 0
Up to 19 months
Secondary outcome [15] 0 0
Part 1B: Overall Survival (OS)
Timepoint [15] 0 0
Up to 19 months
Secondary outcome [16] 0 0
Part 1B: Time to Response
Timepoint [16] 0 0
Up to 19 months
Secondary outcome [17] 0 0
Part 1B: Duration of Response (DoR)
Timepoint [17] 0 0
Up to 19 months
Secondary outcome [18] 0 0
Part 1B: Maximum Observed Concentration (Cmax) of AMG 397
Timepoint [18] 0 0
Up to 6 months
Secondary outcome [19] 0 0
Part 1B: Time of Maximum Observed Concentration (Tmax) of AMG 397
Timepoint [19] 0 0
Up to 6 months
Secondary outcome [20] 0 0
Part 1B: Area Under the Concentration Time Curve (AUC) of AMG 397
Timepoint [20] 0 0
Up to 6 months
Secondary outcome [21] 0 0
Part 1B: Clearance (CL) of AMG 397
Timepoint [21] 0 0
Up to 6 months
Secondary outcome [22] 0 0
Part 1B: Half-life (t1/2) of AMG 397
Timepoint [22] 0 0
Up to 6 months
Secondary outcome [23] 0 0
Part 2A: Objective Response Rate (ORR) for Myelodysplastic Syndrome (MDS) Subjects - Response criteria per Revised International Working Group (IWG).
Timepoint [23] 0 0
Up to 19 months
Secondary outcome [24] 0 0
Part 2A: Objective Response Rate (ORR) for Acute Myeloid Leukemia (AML) Subjects - Response criteria per Revised International Working Group (IWG).
Timepoint [24] 0 0
Up to 19 months
Secondary outcome [25] 0 0
Part 2A: Progression-free survival (PFS)
Timepoint [25] 0 0
Up to 19 months
Secondary outcome [26] 0 0
Part 2A: Overall Survival (OS)
Timepoint [26] 0 0
Up to 19 months
Secondary outcome [27] 0 0
Part 2A: Time to Response
Timepoint [27] 0 0
Up to 19 months
Secondary outcome [28] 0 0
Part 2A: Duration of Response (DoR)
Timepoint [28] 0 0
Up to 19 months
Secondary outcome [29] 0 0
Part 2A: Maximum Observed Concentration (Cmax) of AMG 397
Timepoint [29] 0 0
Up to 6 months
Secondary outcome [30] 0 0
Part 2A: Time of Maximum Observed Concentration (Tmax) of AMG 397
Timepoint [30] 0 0
Up to 6 months
Secondary outcome [31] 0 0
Part 2A: Area Under the Concentration Time Curve (AUC) of AMG 397
Timepoint [31] 0 0
Up to 6 months
Secondary outcome [32] 0 0
Part 2A: Clearance (CL) of AMG 397
Timepoint [32] 0 0
Up to 6 months
Secondary outcome [33] 0 0
Part 2A: Half-life (t1/2) of AMG 397
Timepoint [33] 0 0
Up to 6 months
Secondary outcome [34] 0 0
Part 2B: Objective Response Rate (ORR) for Acute Myeloid Leukemia (AML) Subjects - Response criteria per Revised International Working Group (IWG).
Timepoint [34] 0 0
Up to 19 months
Secondary outcome [35] 0 0
Part 2B: Progression-free survival (PFS)
Timepoint [35] 0 0
Up to 19 months
Secondary outcome [36] 0 0
Part 2B: Overall Survival (OS)
Timepoint [36] 0 0
Up to 19 months
Secondary outcome [37] 0 0
Part 2B: Time to Response
Timepoint [37] 0 0
Up to 19 months
Secondary outcome [38] 0 0
Part 2B: Duration of Response (DoR)
Timepoint [38] 0 0
Up to 19 months
Secondary outcome [39] 0 0
Part 2B: Time of Maximum Observed Concentration (Tmax) of AMG 397
Timepoint [39] 0 0
Up to 6 months
Secondary outcome [40] 0 0
Part 2C: Objective Response Rate (ORR) for Multiple Myeloma (MM) Subjects - Response criteria per International Myeloma Working Group - Uniform Response Criteria (IMWG-URC).
Timepoint [40] 0 0
Up to 19 months
Secondary outcome [41] 0 0
Part 2C: Progression-free survival (PFS)
Timepoint [41] 0 0
Up to 19 months
Secondary outcome [42] 0 0
Part 2C: Overall Survival (OS)
Timepoint [42] 0 0
Up to 19 months
Secondary outcome [43] 0 0
Part 2C: Time to Response
Timepoint [43] 0 0
Up to 19 months
Secondary outcome [44] 0 0
Part 2C: Duration of Response (DoR)
Timepoint [44] 0 0
Up to 19 months
Secondary outcome [45] 0 0
Part 2C: Maximum Observed Concentration (Cmax) of AMG 397
Timepoint [45] 0 0
Up to 6 months
Secondary outcome [46] 0 0
Part 2C: Time of Maximum Observed Concentration (Tmax) of AMG 397
Timepoint [46] 0 0
Up to 6 months
Secondary outcome [47] 0 0
Part 2C: Area Under the Concentration Time Curve (AUC) of AMG 397
Timepoint [47] 0 0
Up to 6 months
Secondary outcome [48] 0 0
Part 2C: Clearance (CL) of AMG 397
Timepoint [48] 0 0
Up to 6 months
Secondary outcome [49] 0 0
Part 2C: Half-life (t1/2) of AMG 397
Timepoint [49] 0 0
Up to 6 months
Secondary outcome [50] 0 0
Part 3A: Objective Response Rate (ORR) for Myelodysplastic Syndrome (MDS) Subjects - Response criteria per Revised International Working Group (IWG).
Timepoint [50] 0 0
Up to 19 months
Secondary outcome [51] 0 0
Part 3A: Overall Survival (OS)
Timepoint [51] 0 0
Up to 19 months
Secondary outcome [52] 0 0
Part 3A: Progression-free survival (PFS)
Timepoint [52] 0 0
Up to 19 months
Secondary outcome [53] 0 0
Part 3A: Time to Response
Timepoint [53] 0 0
Up to 19 months
Secondary outcome [54] 0 0
Part 3A: Duration of Response (DoR)
Timepoint [54] 0 0
Up to 19 months
Secondary outcome [55] 0 0
Part 3A: Maximum Observed Concentration (Cmax) of AMG 397
Timepoint [55] 0 0
Up to 6 months
Secondary outcome [56] 0 0
Part 3A: Maximum Observed Concentration (Cmax) of Azacitidine
Timepoint [56] 0 0
Pre-dose to 8 hours after infusion
Secondary outcome [57] 0 0
Part 3A: Area Under the Concentration Time Curve (AUC) of AMG 397
Timepoint [57] 0 0
Up to 6 months
Secondary outcome [58] 0 0
Part 3A: Area Under the Concentration Time Curve (AUC) of Azacitidine
Timepoint [58] 0 0
Pre-dose to 8 hours after infusion
Secondary outcome [59] 0 0
Part 3A: Clearance (CL) of AMG 397
Timepoint [59] 0 0
Up to 6 months
Secondary outcome [60] 0 0
Part 3A: Clearance (CL) of Azacitidine
Timepoint [60] 0 0
Pre-dose to 8 hours after infusion
Secondary outcome [61] 0 0
Part 3A: Half-life (t1/2) of AMG 397
Timepoint [61] 0 0
Up to 6 months
Secondary outcome [62] 0 0
Part 3A: Half-life (t1/2) of Azacitidine
Timepoint [62] 0 0
Pre-dose to 8 hours after infusion
Secondary outcome [63] 0 0
Part 3B: Objective Response Rate (ORR) for Acute Myeloid Leukemia (AML) Subjects - Response criteria per 2017 European LeukemiaNet (ELN) criteria.
Timepoint [63] 0 0
Up to 19 months
Secondary outcome [64] 0 0
Part 3B: Progression-free survival (PFS)
Timepoint [64] 0 0
Up to 19 months
Secondary outcome [65] 0 0
Part 3B: Overall Survival (OS)
Timepoint [65] 0 0
Up to 19 months
Secondary outcome [66] 0 0
Part 3B: Time to Response
Timepoint [66] 0 0
Up to 19 months
Secondary outcome [67] 0 0
Part 3B: Duration of Response (DoR)
Timepoint [67] 0 0
Up to 19 months
Secondary outcome [68] 0 0
Part 3B: Maximum Observed Concentration (Cmax) of AMG 397
Timepoint [68] 0 0
Up to 6 months
Secondary outcome [69] 0 0
Part 3B: Maximum Observed Concentration (Cmax) of Azacitidine
Timepoint [69] 0 0
Pre-dose to 8 hours after infusion
Secondary outcome [70] 0 0
Part 3B: Area Under the Concentration Time Curve (AUC) of AMG 397
Timepoint [70] 0 0
Up to 6 months
Secondary outcome [71] 0 0
Part 3B: Area Under the Concentration Time Curve (AUC) of Azacitidine
Timepoint [71] 0 0
Pre-dose to 8 hours after infusion
Secondary outcome [72] 0 0
Part 3B: Clearance (CL) of AMG 397
Timepoint [72] 0 0
Up to 6 months
Secondary outcome [73] 0 0
Part 3B: Clearance (CL) of Azacitidine
Timepoint [73] 0 0
Pre-dose to 8 hours after infusion
Secondary outcome [74] 0 0
Part 3B: Half-life (t1/2) of AMG 397
Timepoint [74] 0 0
Up to 6 months
Secondary outcome [75] 0 0
Part 3B: Half-life (t1/2) of Azacitidine
Timepoint [75] 0 0
Pre-dose to 8 hours after infusion
Secondary outcome [76] 0 0
Part 3C: Objective Response Rate (ORR) for Multiple Myeloma (MM) Subjects - Response criteria per International Myeloma Working Group - Uniform Response Criteria (IMWG-URC).
Timepoint [76] 0 0
Up to 19 months
Secondary outcome [77] 0 0
Part 3C: Progression-free survival (PFS)
Timepoint [77] 0 0
Up to 19 months
Secondary outcome [78] 0 0
Part 3C: Overall Survival (OS)
Timepoint [78] 0 0
Up to 19 months
Secondary outcome [79] 0 0
Part 3C: Time to Response
Timepoint [79] 0 0
Up to 19 months
Secondary outcome [80] 0 0
Part 3C: Duration of Response (DoR)
Timepoint [80] 0 0
Up to 19 months
Secondary outcome [81] 0 0
Part 3C: Maximum Observed Concentration (Cmax) of AMG 397
Timepoint [81] 0 0
Up to 6 months
Secondary outcome [82] 0 0
Part 3C: Maximum Observed Concentration (Cmax) of Dexamethasone
Timepoint [82] 0 0
Pre-dose to 48 hours after infusion
Secondary outcome [83] 0 0
Part 3C: Area Under the Concentration Time Curve (AUC) of AMG 397
Timepoint [83] 0 0
Up to 6 months
Secondary outcome [84] 0 0
Part 3C: Area Under the Concentration Time Curve (AUC) of Dexamethasone
Timepoint [84] 0 0
Pre-dose to 48 hours after infusion
Secondary outcome [85] 0 0
Part 3C: Clearance (CL) of AMG 397
Timepoint [85] 0 0
Up to 6 months
Secondary outcome [86] 0 0
Part 3C: Clearance (CL) of Dexamethasone
Timepoint [86] 0 0
Pre-dose to 48 hours after infusion
Secondary outcome [87] 0 0
Part 3C: Half-life (t1/2) of AMG 397
Timepoint [87] 0 0
Up to 6 months
Secondary outcome [88] 0 0
Part 3C: Half-life (t1/2) of Dexamethasone
Timepoint [88] 0 0
Pre-dose to 48 hours after infusion

Eligibility
Key inclusion criteria
- Subject has provided informed consent prior to initiation of any study-specific
activities/procedures

- Age = 18 years old

- Pathologically-documented, definitively-diagnosed relapsed or refractory multiple
myeloma (MM), myelodysplastic syndrome (MDS), or acute myeloid leukemia (AML) and is
intolerant to, or considered ineligible for available therapies known to provide
clinical benefit

- MM subjects only: Measurable disease per the International Myeloma Working Group
(IMWG) response criteria (assessed within 21 days prior to enrollment), as indicated
by one or more of the following: cytogenic risk factor: 1q21 amplification/gain, serum
M-protein = 0.5 g/dL, Urine M-protein = 200 mg/24 hours. For Subjects who do not meet
1 of the 2 prior criteria: Serum Free Light Chain (sFLC) = 10 mg/dL (= 100 mg/L) and
an abnormal sFLC ratio (< 0.26 or > 1.65) as per the IMWG response criteria

- MM subjects only: Hematological function, as follows without transfusion or growth
factor support within 2 weeks prior to study day 1: absolute neutrophil count = 1.0 X
109/L, hemoglobin > 8 g/dL and platelet count = 75 X 109/L

- AML subjects only: Pathologically confirmed diagnosis of AML as defined by the World
Health Organisation (WHO) Classification, more than 5% blasts in bone marrow and
persisting or recurring following one or more treatment courses

- MDS subjects only: pathologically confirmed diagnosis of MDS as defined by the WHO
Classification, intermediate and high risk MDS and intolerant or refractory to HMA
treatment

- Eastern Cooperative Oncology Group (ECOG) performance status of = 2

- Life expectancy of > 3 months, based on the opinion of the investigator

- Able to swallow and retain orally administered medication and does not have any
clinically significant gastrointestinal abnormalities that may alter absorption.

- Hepatic function, as follows:

- aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 3 x upper
limit of normal (ULN)

- total bilirubin (TBL) < 1.5 X ULN (except subjects with Gilbert's syndrome)

- Cardiac function, as follows:

- Cardiac ejection fraction = 50% and no evidence of pericardial effusion as
determined by echocardiogram or multigated acquisition (MUGA) scan

- no ECG findings representing a recent cardiac injury within 6 months before
enrollment

- Renal function as follows:

- Calculated or measured creatinine clearance (CrCl) of = 30 mL/minute calculated
using the formula of Cockcroft and Gault [(140 - Age) × Mass (kg) / (72 × serum
creatinine mg/dL)]. Multiply result by 0.85 if female
Minimum age
18 Years
Maximum age
No limit
Gender
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
Disease Related

- Previously received an allogeneic stem cell transplant within 6 months of study day 1
OR having signs or symptoms of acute or chronic graft-versus-host disease

- Autologous stem cell transplant < 90 days before enrollment

- Candidates for stem cell transplant should have failed or are not considered eligible
for either allogeneic and autologous transplant

Other Medical Conditions

- History of other malignancy except:

- Malignancy treated with curative intent and with no known active disease present
for = 2 years before enrollment and felt to be at low risk for recurrence by the
treating physician

- Adequately treated non-melanoma skin cancer or lentigo maligna without evidence
of disease

- Adequately treated cervical carcinoma in situ without evidence of disease

- Adequately treated breast ductal carcinoma in situ without evidence of disease

- Prostatic intraepithelial neoplasia without evidence of prostate cancer

- Adequately treated urothelial papillary noninvasive carcinoma or carcinoma in
situ

- Myocardial infarction within 6 months before enrollment

- Symptomatic congestive heart failure (New York Heart Association > Class II)

- History of arterial thrombosis (eg, stroke or transient ischemic attack) in the past 6
months before enrollment

- Uncontrollable active infection requiring intravenous anti-infective treatments within
1 week before enrollment

- Known positive results for human immunodeficiency virus (HIV)

- Active hepatitis B and C based on the following results: Positive for hepatitis B
surface antigen (HBsAg) (indicative of chronic, hepatitis B or recent acute hepatitis
B), Negative HBsAg and positive for hepatitis B core antibody: hepatitis B virus DNA
by polymerase chain reaction (PCR) is necessary. Detectable hepatitis B virus DNA
suggests occult hepatitis B. Positive Hepatitis C virus antibody (HCVAb): hepatitis C
virus RNA by PCR is necessary. Detectable hepatitis C virus RNA suggests chronic
hepatitis C

- Unresolved toxicities from prior anti-tumor therapy, defined as not having resolved to
Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 grade 1, or to
levels dictated in the eligibility criteria with the exception of grade 2peripheral
neuropathy, alopecia or toxicities from prior anti-tumor therapy that are considered
irreversible (defined as having been present and stable for > 4 weeks prior to study
day 1 may be allowed if they are not otherwise described in the exclusion criteria AND
there is agreement to allow by both the investigator and sponsor)

- Antitumor therapy (chemotherapy, antibody therapy, molecular-targeted therapy,
retinoid therapy, or investigational agent or procedures) within 14 days of day 1

- Prior systemic radiation therapy must have been completed at least 28 days before
study day 1. Prior focal radiotherapy completed at 14 days before study day 1

- Females of reproductive potential who are unwilling to practice acceptable methods of
highly effective contraception while on study through 8 months after receiving the
last dose of study drug. Males who are unwilling to practice sexual abstinence
(refrain from heterosexual intercourse) or use a condom with or without spermicide
while on study through 5 months after receiving the last dose of study drug if
sexually active with a female of childbearing potential

- Females who are lactating/breastfeeding or who plan to breastfeed while on study
through 8 months after receiving the last dose of study drug

- Females with a positive pregnancy test or planning to become pregnant while on study
through 8 months after receiving the last dose of study drug

- Males who are unwilling to abstain from sperm donation while on study through 8 months
after receiving the last dose of study drug

- History or evidence of any other clinically significant disorder, condition or disease
that, in the opinion of the investigator or Amgen physician, if consulted, would pose
a risk to subject safety or interfere with the study evaluation, procedures or
completion

- Use of any over-the-counter or prescription medications within 14 days or 5 half-lives
(whichever is longer), prior to study day 1 that was not reviewed and approved by the
principal investigator and the Amgen medical monitor

- Use of herbal medicines (eg, St. John's wort), vitamins, and supplements consumed by
the subject within 14 days prior to study day 1 that was not reviewed and approved by
the principal investigator and the Amgen medical monitor

- Use of any known inhibitors of P-gp within 14 days or 5 half-lives (whichever is
longer) or grapefruit juice or grapefruit containing products within 7 days prior to
study day 1 that was not reviewed and approved by the principal investigator and the
Amgen medical monitor

- Use of known CYP3A4 sensitive substrates, (with a narrow therapeutic window), within
14 days or 5 half-lives (whichever is longer) of the drug or its major active
metabolite, whichever is longer, prior to study day 1 that was not reviewed and
approved by the principal investigator and the Amgen medical monitor

- Use of known P-gp substrates (with a narrow therapeutic window) within 14 days or 5
half-lives (whichever is longer) prior to study day 1 that was not reviewed and
approved by the principal investigator and the Amgen medical monitor

- Subject likely to not be available to complete all protocol-required study visits or
procedures, and/or to comply with all required study procedures (eg, long term
follow-up) to the best of the subject and investigator's knowledge

- Known sensitivity to any of the products or component to be administered during dosing

- MM subjects with any of the following criteria are excluded:

- Multiple myeloma with IgM subtype

- POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein,
and skin changes)

- Existing plasma cell leukemia

- Waldenstrom's macroglobulinemia

- Amyloidosis

- AML subjects with the following criteria are excluded:

- Circulating white blood cells > 25,000/µl. Hydroxyurea to control peripheral
blood leukemic cell counts, within 24 hours of study day 1 is permitted

- Promyelocytic leukemia

- AML/MDS subjects fit for intensive salvage therapy

- Subjects with elevated cardiac troponin above the manufacturer's 99th percentile upper
reference limit for ADVIA Centaur XP assay at screening performed by the central
laboratory (Covance)

- Subjects with evidence of recent cardiac injury at screening based on creatine
kinase-muscle/brain (CK-MB), N-terminal prohormone of brain natriuretic peptide
(NT-pro-BNP), and ECG assessments at screening

- Subjects with MDS that are eligible for hematopoietic stem cell transplant (HSCT)

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Other
Other design features
Phase
Phase 1
Type of endpoint(s)
Statistical methods / analysis

Recruitment
Recruitment status
Terminated
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW,QLD,VIC
Recruitment hospital [1] 0 0
Research Site - Camperdown
Recruitment hospital [2] 0 0
Research Site - Woolloongabba
Recruitment hospital [3] 0 0
Research Site - Melbourne
Recruitment postcode(s) [1] 0 0
02050 - Camperdown
Recruitment postcode(s) [2] 0 0
4102 - Woolloongabba
Recruitment postcode(s) [3] 0 0
3004 - Melbourne
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
Arizona
Country [3] 0 0
United States of America
State/province [3] 0 0
Florida
Country [4] 0 0
United States of America
State/province [4] 0 0
Kansas
Country [5] 0 0
United States of America
State/province [5] 0 0
Maryland
Country [6] 0 0
United States of America
State/province [6] 0 0
Massachusetts
Country [7] 0 0
United States of America
State/province [7] 0 0
Minnesota
Country [8] 0 0
United States of America
State/province [8] 0 0
Missouri
Country [9] 0 0
United States of America
State/province [9] 0 0
New York
Country [10] 0 0
United States of America
State/province [10] 0 0
Texas
Country [11] 0 0
United States of America
State/province [11] 0 0
Wisconsin
Country [12] 0 0
France
State/province [12] 0 0
Marseille Cedex 09
Country [13] 0 0
France
State/province [13] 0 0
Villejuif
Country [14] 0 0
Greece
State/province [14] 0 0
Athens
Country [15] 0 0
Italy
State/province [15] 0 0
Bergamo
Country [16] 0 0
Italy
State/province [16] 0 0
Bologna
Country [17] 0 0
Japan
State/province [17] 0 0
Gifu

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Amgen
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Evaluate the safety and tolerability of AMG 397. Estimate the maximum tolerated doses (MTDs)
and/or biologically active doses.
Trial website
https://clinicaltrials.gov/show/NCT03465540
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
MD
Address 0 0
Amgen
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

Summary results
For IPD and results data, please see https://clinicaltrials.gov/show/NCT03465540